Compare Deckers Outdoor Corp (DECK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs TG Therapeutics Inc — how do they compare? Deckers Outdoor Corp trades at $107.36 (market cap $14.80B), while TG Therapeutics Inc trades at $55.31 (market cap $8.41B). The key difference: Deckers Outdoor Corp is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| DECK | TGTX | |
|---|---|---|
Market Cap | $14.80B | $8.41B |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $59.06 |
52-Week Low | $79.54 | $26.39 |
Enterprise Value | $13.27B | $8.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $107.80, up 1.71% for the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding the $0.83 estimate. Revenue grew to $4.99B in 2025, and net income reached $966M. Analyst consensus price target is $122.44, suggesting potential upside. Recent news highlights robust brand momentum for UGG and HOKA, with international sales growth offsetting domestic stagnation.
Outlook remains positive driven by earnings growth and strong cash flow, but risks include reliance on key brands and competitive pressures. The stock offers a reasonable valuation with a P/E of 15.36 and high profitability metrics, though technical indicators show some overbought conditions near-term.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
